Mylan (NASDAQ: MYL) is shipping out a new generic version of a branded treatment. The company announced today that its American subsidiary, Mylan Pharmaceuticals, has begun the sale of Repaglinide, the generic form of Novo Nordisk's (NYSE: NVO) Prandin, in the U.S. market. Repaglinide tablets are sold in 0.5 milligram, 1 milligram, and 2 milligram configurations.

Repaglinide/Prandin is a treatment described by Mylan as "an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus."

Mylan is one of the more prominent generic producers on the market. Although the value of branded drugs losing patent protection dropped by around $25 billion to hit $30 billion in 2013, that number is expected to rise to $34 billion this year and balloon to $66 billion in 2015.  

Fool contributor Eric Volkman has no position in any stocks mentioned. Nor does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.